145results about "Aldehyde active ingredients" patented technology

Methods of treating, suppressing, or reducing the severity of a liver cancer in a subject are described herein. The disclosed methods involve administering a therapeutically effective amount of a composition including safranal or its pharmaceutically acceptable pro-drug, and a pharmaceutically acceptable carrier to the subject. The disclosed methods may be used to treat, suppress, or reduce the severity of various liver cancers, including hepatocellular carcinoma (HCC), fibrolamellar HCC, cholangiocarcinoma, angiosarcoma, a metastatic liver cancer, and combinations thereof.

The invention relates to the technical field of plant extraction, and provides a plurality of phenolic compounds in senecio scandens, and a preparation method and application thereof. The method comprises the following steps: crushing senecio scandens, adding ethyl acetate, and performing ultrasonic heating, stirring and extracting to obtain an extracting solution; carrying out rotary evaporation and vacuum concentration on the extracting solution to obtain a crude extract; dissolving the crude extract by using absolute ethyl alcohol through ultrasonic heating, carrying out gradient elution through a macroporous adsorption resin chromatographic column, and collecting an ethanol water eluent; and concentrating the ethanol water eluent under reduced pressure, stirring with a reverse-phase filler, loading with a dry method, packing with a wet method, and sequentially performing isocratic elution with a reverse-phase chromatographic column and purification with a gel column. The dissolution efficiency of phenolic compounds in senecio scandens is improved through ultrasonic and mild heating, the problems that components are degraded due to high temperature in traditional reflux extraction and time and solvent are consumed in dipping extraction are solved, and target component residues are reduced; and then through gradient elution of a chromatographic separation column, isocratic elution of a reversed-phase chromatographic column and purification of a gel column, the problem that phenols are similar in structure and easy to co-elute is accurately solved.

The present disclosure relates to compositions for improving gut health and / or milk production in ruminants, comprising: at least one organic acid chosen from sorbic acid, fumaric acid, malic acid, lactic acid, citric acid, formic acid, salts thereof and mixtures thereof; at least one essential oil chosen from thymol, eugenol, vanillin, thyme oil, carvacrol, cinnamaldehyde, clove leaf essential oil, and mixtures thereof; at least one bacterial fermentation product chosen from bacterial fermentation products of a Bacillus fermentation product, a Streptomyces fermentation product, an Aspergillus fermentation product, a Streptococcus fermentation product, a Paenibacillus fermentation product and mixtures thereof; at least one plant extract chosen from a saponin, a Yucca extract, a Quillaja extract and mixtures thereof; and at least one controlled release matrix.

The invention relates to a hybrid nano assembly for dual synergistic chemotherapy as well as a preparation method and application of the hybrid nano assembly, and belongs to the technical field of pharmaceutical preparations. The invention relates to a hybrid nano assembly for dual synergistic chemotherapy, which is formed by co-assembling a cabazitaxel prodrug and gossypol under hydrophobic action and hydrogen bond driving, and is modified by adopting a PEG (Polyethylene Glycol) modifier, the molar ratio of the cabazitaxel prodrug to the gossypol is 1: (1-7), and the ratio of the total mass of the cabazitaxel prodrug and the gossypol to the mass of the PEG modifier is 4: 1. A cabazitaxel prodrug and a sensitizer gossypol are co-assembled to obtain a hybrid nano assembly, the hybrid nano assembly is oxygenated to obtain the oxygen-carrying preparation, the nano assembly and the oxygen-carrying preparation are simple and convenient to prepare and high in drug loading efficiency, and efficient co-loading of drugs can be achieved; meanwhile, the curative effect of chemotherapy can be enhanced through dual mechanisms of relieving tumor hypoxia and promoting tumor apoptosis, and the pharmaceutical composition has a good clinical application prospect.

The invention discloses a salmonella virulent bacteriophage vBSalPNW15 and application thereof, the bacteriophage is separated from farm sewage, belongs to a long-tail bacteriophage family, has a regular icosahedron head and a long-tail structure, and keeps stable under the conditions that the pH is 4-13 and the temperature is 40-60 DEG C. Genomic analysis shows that the kit does not contain virulence genes and drug-resistant genes and is good in safety. The bacteriophage and cinnamyl aldehyde are combined to be used for preventing and treating salmonella infection, both the bacteriophage and cinnamyl aldehyde show a remarkable synergistic bacteriostatic effect (FICI = 0.5) in vitro and in vivo, and the bacteriophage and cinnamyl aldehyde can effectively inhibit growth of multi-drug-resistant salmonella, remove biological membranes, relieve tissue pathological damage and remarkably improve the survival rate of chicks. The invention provides a safe and efficient antibiotic replacement scheme for preventing and treating salmonella infection, and is suitable for the fields of livestock and poultry breeding and food safety.

The disclosure relates to solid and liquid compositions for reducing lactation, improving health, reducing the risk and or occurrence of intramammary infections, dry-off related stress, dry-off related inflammation, and / or dry-off related infections. A preferred compound is di-n-propyl disulfide.

A composition comprises β-pinene, bomeol, cinnamic aldehyde, citral, d-limonene, eucalyptol, eugenol, famesol, linalool, thymol, and vanillin. In addition, a method for use of the composition as an antibacterial and antiviral agent is also disclosed.

The application belongs to the technical field of medicine and pharmacy, and particularly relates to application of vanillin in preparation of a Klebsiella pneumoniae capsule inhibitor. The application relates to application of vanillin in preparation of an inhibitor for inhibiting formation, adhesion or function of a Klebsiella pneumoniae capsule, and related antibacterial or anti-infection products, wherein the vanillin reduces pathogenicity of Klebsiella pneumoniae by inhibiting capsule synthesis. It is disclosed that the vanillin can effectively inhibit formation of a Klebsiella pneumoniae capsule and reduce viscosity of bacteria, and can effectively treat mice infected with Klebsiella pneumoniae.

The invention provides a composite antibiotic-replacing microcapsule preparation as well as a preparation method and application thereof. The composite antibiotic-replacing microcapsule preparation comprises a core material as well as an inner-layer wall material and an outer-layer wall material which are sequentially coated outside the core material, wherein the core material comprises a Chinese herbal medicine extract, plant essential oil and probiotics, the Chinese herbal medicine extract comprises forsythin, astragalus polysaccharide and atractylenolide III, the plant essential oil comprises origanum oil and cinnamyl aldehyde, and the probiotics comprise bacillus subtilis; the inner-layer wall material is prepared by crosslinking sodium alginate and calcium chloride, and the outer-layer wall material comprises chitosan. The traditional Chinese medicine composition has the characteristics of synergistic interaction, high stability and good intestinal tract targeting property, and can improve the resistance replacement effect.

The invention relates to a preparation method of an animal anti-diarrhea feed additive containing delinted moxa powder and essential oil. The preparation method of the animal anti-diarrhea feed additive containing the delinted moxa powder and the essential oil comprises the following steps: mixing essential oil components thymol and cinnamyl aldehyde, and stirring at 35-65 DEG C until the essential oil components are dissolved to obtain an essential oil solution; the preparation method comprises the following steps: mixing antioxidants BHA and PG, citric acid and ethanol, and stirring until dissolving to obtain an ethanol solution; mixing the ethanol solution with stone powder, and drying to remove ethanol to obtain a solid mixture; mixing the solid mixture with the essential oil solution, adding delinted moxa powder, and stirring uniformly; according to the preparation method of the animal anti-diarrhea feed additive containing the delinted moxa powder and the essential oil, stable combination of the essential oil and the delinted moxa powder is achieved, the diarrhea morbidity and mortality are remarkably reduced in animal experiments, and the effect is better than that of independent use of the essential oil.

This invention relates to the field of functional food technology, and more particularly to the application of safflower honey, or safflower honey extract, in enhancing the activity of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). The invention has found that safflower honey, or safflower honey extract, can effectively enhance ADH and ALDH activity, thereby promoting alcohol metabolism and achieving a hangover-relieving effect. Further research on the extract revealed that a mixture of syringaldehyde, riboflavin, lutein, luciferin, and three p-coumaroyl spermidine plays a key role in enhancing ADH and ALDH activity, thus providing an application of this mixture in hangover relief. The application of safflower honey and its extract provided by this invention has high application value for developing foods and health products with hangover-relieving effects.

Various methods and compositions of treating 4-hydroxyphenylpyruvate dioxygenase-like (HPDL)-related diseases or disorders are presented herein. Also presented herein are methods of increasing CoQ10 biosynthesis, and methods of determining whether a subject will benefit from a CoQ10 or CoQ10 alternative treatment. Also presented herein are pharmaceutical compositions and dosage forms comprising 4-hydroxymandelic acid (4-HMA), and / or its metabolites. Further presented herein are compounds that inhibit 4-hydroxyphenylpyruvate dioxygenase-like (HPDL). Further presented herein are methods of identifying and / or assessing modulators of HPDL. Yet further presented herein are example methods and systems for isotopic labelling in cells by metabolizing cells in the presence of gaseous isotopic tracer.

The objective is to suppress or improve the decline in cognitive function speed or reaction time. [Solution] The above problem can be solved by a composition for suppressing or improving the decline of cognitive function speed or reaction time, which contains cumin aldehyde, or cumin (Cuminum cyminum) containing cumin aldehyde or a processed product thereof.

The application relates to the technical field of biological medicine, in particular to a compound with a conjugated structure containing an alpha, beta-unsaturated aldehyde and application thereof. The compound can covalently modify Sortase A enzyme of propionibacterium acnes through alpha, beta-unsaturated aldehyde, inhibit transpeptidation catalysis and adhesion of gram-positive bacteria (for example, methicillin-resistant staphylococcus aureus, streptococcus mutans and propionibacterium acnes), block anchoring of membrane proteins, inhibit growth of gram-positive bacteria or kill bacteria; conjugated groups with different electric effects and steric effects are screened to adjust the covalent modification efficiency of alpha, beta-unsaturated aldehyde and Sortase A enzyme, strengthen the activity of the compound in inhibiting Sortase A enzyme, thereby improve the antibacterial activity of the compound, and further make the compound with the conjugated structure containing the alpha, beta-unsaturated aldehyde in the application be applied to the fields of biological medicine and cosmetics as an antibacterial component.

To provide an excellent nitrotyrosine reducing agent that can directly degrade already formed nitrated protein.SOLUTION: Provided is a nitrotyrosine reducing agent that contains at least one compound selected from the group consisting of (1) to (3) below. (1) A compound that has at least three substituents on the benzene ring and satisfies any of the following (A) to (C): (A) all of said at least three substituents are -OH; (B) of the at least three substituents, the first substituent is -C(=O)H, -C(=O)OH or -C(=O)Ra, and the second substituent group is -OH and the third substituent is -OH or -Rb; (C) the first substituent and the second substituent are bonded to neighboring carbon atoms on the benzene ring, and together with the carbon atoms to which they are bonded form a fused heterocycle, and the third substituent is -OH or -Rc, (2) Gibberellin, and (3) Genipin.SELECTED DRAWING: None

The present invention relates to novel compositions comprising a retinoid mixture of cis and trans isomers of retinyl esters, specifically retinyl acetate, with a cis / trans ratio of less than 0.03, and their use for the treatment, prevention and alleviation of diseases and conditions treatable with 5-HT2B serotonin receptor antagonists, including, but not limited to, diseases or conditions selected from migraine headaches, anxiety, ocular hypotension, valvular heart disease, irritable bowel syndrome, and MDMA (commonly referred to as "ecstasy") abuse.

Cosmetic and pharmaceutical formulations containing specific amino acid blends are described herein. These formulations strengthen and enhance the barrier function of skin epithelial cells, thereby reducing water loss from the skin and restoring and / or maintaining the structural integrity of the skin, epithelial differentiation, cell-cell adhesion, and intracellular signaling. The formulations described herein contain a therapeutically effective amount of a free amino acid or a peptide combination of amino acids, and a therapeutically effective amount of a plant extract for skin barrier repair or a therapeutically effective amount of a retinoid for improving skin moisture. Also provided are injectable formulations described herein for treating subjects suffering from osteoarthritis or its symptoms. Methods for administering these formulations for cosmetic and / or therapeutic purposes, and their uses for the same, such as in the preparation of pharmaceuticals, are also described herein.

The present invention primarily relates to a combination remedy for reducing appetite and / or for imparting a feeling of fullness and / or for reducing energy absorption and / or for reducing body weight. Furthermore, the present invention relates to a medical use of the combination remedy, in particular for treating overweight and adiposity and for preventing cardiovascular diseases, stroke, diabetes, as well as joint damage and wear of the spinal column, and to a non-therapeutic use of the combination remedy. The present invention focuses in particular on the use of the combination remedy in order to impart a feeling of fullness and / or to reduce energy absorption and / or to reduce body weight. Finally, the present invention relates to the use of the combination remedy in order to produce an orally consumable preparation or a food additive, and to an orally consumable preparation or food additive produced therefrom.

The invention discloses a preparation method and application of cinnamyl aldehyde nanoparticles, and the preparation method is characterized in that cinnamyl aldehyde is used as a functional component, zein is used as a carrier, sodium caseinate is used as a stabilizer, and pectin is used as a stabilizer and an adhesive to prepare the cinnamyl aldehyde nanoparticles. Experiments prove that the cinnamyl aldehyde nano-particles prepared by the invention can significantly improve the stability of cinnamyl aldehyde, enhance the antibacterial activity of cinnamyl aldehyde to staphylococcus aureus, and provide more choices for development and utilization of cinnamyl aldehyde.

The invention discloses a cinnamyl aldehyde modified montmorillonite nanosheet capable of inhibiting bacterial quorum sensing as well as a preparation method and application of the cinnamyl aldehyde modified montmorillonite nanosheet. According to the modified nanosheet, a two-dimensional montmorillonite nanosheet is taken as a carrier, and cinnamyl aldehyde is intercalated into an interlayer region of the two-dimensional montmorillonite nanosheet. The modified montmorillonite nanosheet can achieve the effect of inhibiting inflammation by inhibiting bacterial quorum sensing and adjusting the abundance of intestinal microorganisms, effectively relieves symptoms induced by IBD, has good stability, biocompatibility and biodegradability, and can be used for treating inflammatory bowel diseases.

The present invention discloses a composition and method for treating arthritis. The composition comprises a binary blend of molecules including citral, methyl cinnamate, and epicurzerenone. The binary blend exhibits synergistic efficacy in modulating inflammatory cytokines. The citral, epicurzerenone, and methyl cinnamate, are derived from essential oils of Cymbopogon citratus, Hedychium spicatum, and Zanthoxylum armatum, respectively. Both individual and binary blend exhibits downregulation of pro-inflammatory cytokines IL-2, IL-6, and TNF-α, and upregulation of anti-inflammatory cytokine IL-10

The invention relates to the technical field of aquaculture disease control, in particular to preparation of a citral preparation and application of the citral preparation in aquaculture, the preparation method comprises the following steps: step 1, adding a compound emulsifier into a co-solution, and uniformly stirring and mixing to obtain an emulsion; step 2, adding the active component into the emulsified liquid, and continuously stirring to form primary emulsion; and step 3, adding a stabilizer into the primary emulsion, stirring and mixing, homogenizing at high pressure, and cooling to room temperature to obtain the citral preparation. The citral preparation prepared by the invention has a strong antibacterial property, and the preparation process of the preparation is simple and convenient and does not need to depend on special equipment, so that the production cost is remarkably reduced, and the realization of large-scale mass production is facilitated; the device is flexible and convenient to operate, can be mixed into feed to be added for use, can also be sprayed through water, and can fully meet diversified scene requirements of aquaculture.

The invention discloses a preparation method of chloral hydrate oral liquid, which comprises the following steps: 1) preparation of chloral hydrate microspheres: dissolving chloral hydrate in an organic solvent, and then adding a carrier material into the solution to obtain an oil phase; adding a surfactant into deionized water to form a water phase; slowly dropwise adding the oil phase into the water phase while stirring and performing ultrasonic treatment to obtain an emulsion; continuously stirring the emulsion, removing the organic solvent, gradually solidifying the medicine and the carrier material in the oil phase to form microspheres, washing, separating and drying to obtain chloral hydrate microspheres; 2) preparation of chloral hydrate oral liquid: dissolving sorbitol in water to obtain a sorbitol aqueous solution; and adding the chloral hydrate microspheres into a sorbitol aqueous solution to obtain the chloral hydrate oral liquid. The chloral hydrate oral liquid prepared by the method has relatively high stability, and meanwhile, the acceptability of a patient is improved.

The present disclosure relates to a microbial oil composition comprising retinoids and fatty acids; a cosmetic composition comprising the microbial oil composition; a food composition comprising the microbial oil composition; a feed composition comprising the microbial oil composition; and a preparation method thereof.

Provided are human therapeutic compositions including a compound comprising a plurality of fused polycyclic moieties and a linker moiety. In certain embodiments, the compound is a reaction product of an aldehyde and a harmine component. The compositions exhibit anti-cancer properties, particularly against lymphoma, leukemia, pancreatic, endometrial, ovarian, gastric, breast, renal, cervical, head and neck, and myeloma cell lines.

The invention relates to the technical field of novel nano materials, and discloses a cabazitaxel-loaded pH / ROS dual-responsive nano material and a preparation method and application thereof.The cabazitaxel-loaded pH / ROS dual-responsive nano material takes a pH / ROS dual-responsive material as a carrier, cabazitaxel is loaded on the carrier, and the pH / ROS dual-responsive material is formed by coupling cyclodextrin and cinnamyl aldehyde main components CA and HPAP. In-vitro and in-vivo experiments show that the CBZ / FA-CA-OCD NPs can be enriched in tumor tissues, and the CBZ / FA-CA-OCD NPs can be taken in by PC-3 and LNCaP cells through FA-mediated endocytosis. The enriched nanoparticles can quickly release cabazitaxel in an acidic microenvironment and / or a high-active oxygen microenvironment, so that the growth of prostatic cancer is effectively inhibited. The CBZ / FA-CA-OCD NPs is combined with an anti-PD-1 antibody for use, so that the infiltration of CD8 < + > and CD4 < + > T cells can be obviously increased, the immunosuppression microenvironment of prostatic cancer is reversed, and the tumor growth is obviously inhibited. The invention provides a promising strategy for regulating the intestinal flora to improve the effectiveness of the chemotherapy-immunity combined therapy for prostatic cancer.

The present invention relates to a composition comprising (i) an extract of Crocus sativus comprising at least safranal, and (ii) an extract of Cannabis sativa comprising cannabidiol (CBD) and uses thereof as a pharmaceutical product, a food supplement, a nutritional product, a cosmetic product, or a liquid suitable for electronic cigarettes.

This invention provides the application of Lactaroviolin, derived from macrofungi of the genus *Lactarius*, in the preparation of products for treating MASLD, belonging to the field of biopharmaceutical technology. The key technical point is the application of Lactaroviolin or its derivatives as the main component in the preparation of products for treating MASLD; wherein the products for treating MASLD contain Lactaroviolin or its derivatives as the main component. This invention utilizes Lactaroviolin to significantly reduce lipid deposition, glucose tolerance, and insulin resistance in the liver of HFD mice, thereby treating MASLD. Therefore, Lactaroviolin holds promise for development as a biopharmaceutical formulation for treating MASLD.

Described herein are methods of treating a human child including administering to the human child a compound selected from epigallocatechin gallate (EGCG), or a derivative thereof selected from epicatechin (EC), epigallocatechin (RGC) and epicatechin gallate (ECG), sulforaphane, olive oil, phylloquinone, quercetin, safranal, hydroxtyrosol, menaquinone-4, menaquinone-7, oleocanthal, peptide Ins-1 B9-23 19CAM22R-E, peptide Ins-1 B12-23-19CAM, peptide Ins-1 B12-23 19CAM22R-E, or a combination of any of the foregoing, wherein administration of the treatment is started between birth and six months of age. Also described are methods of treating a pregnant human or a nursing human mother who has recently given birth to an infant. Further described are insulin B chain mimotope peptides.

It is an object of the present invention to provide a composition for effectively preventing or treating Malassezia skin diseases.SOLUTION: The above problem can be solved by a composition for preventing or treating Malassezia dermatosis comprising citral of the present invention as an active ingredient, or a method for preventing or treating Malassezia dermatosis of an animal comprising a step of bringing an effective amount of citral into contact with the skin of an animal (excluding human).SELECTED DRAWING: None